drugset / Trial / NCT06365788
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Phase 2
Recruiting
53 enrolled
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company · collabKom Op Tegen Kanker · collabTeva Pharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
Timeline
- Start
- 2024-04-08
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |